Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

2 Apr 2019 07:00

RNS Number : 7522U
Intercede Group PLC
02 April 2019
 

 

 

 

2 April 2019

 

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

 

Receipt of $4.3m Order

Trading Update

 

 

Intercede, the leading specialist in digital identity, credential management and secure mobility, is pleased to announce that a large US Federal Government order totaling $4.3m was received on 29 March 2019. The order includes software licenses and annual support & maintenance; $2.05m (£1.57m) of which will be recognised in the financial year ended 31 March 2019.

 

Subject to the completion of the year end audit, revenues for the year ended 31 March 2019 are expected to be in excess of £10.0m, which is ahead of market expectations and approximately 10% higher than the previous financial year. This reflects the impact of follow on orders from existing customers plus new contract wins via partners in the US, Europe and SE Asia. The establishment and further development of these and other partner relationships is critical for the Group's future growth prospects.

 

The combined effect of increased revenues and action taken to reduce the cost base, is expected to result in a return to profitability at both operating profit level (2018: £4.5m operating loss) and after interest and tax (2018: £3.8m loss for the year).

 

As at 31 March 2019, gross cash balances totalled £3.2m (2018: £2.3m).

 

Further detail will be provided within Intercede's final results which are expected to be published in June 2019.

 

 

ENQUIRIES

 

Intercede Group plc Tel. +44 (0)1455 558 111

Klaas van der Leest, Chief Executive

Andrew Walker, Finance Director

 

finnCap Tel. +44 (0)20 7220 0500

Stuart Andrews, Corporate Finance

Simon Hicks, Corporate Finance

 

 

About Intercede

 

Intercede is a cybersecurity company specialising in digital identities, derived credentials and access control, enabling digital trust in a mobile world.

 

Headquartered in the UK, with offices in the US, we believe in a connected world in which people and technology are free to exchange information securely, and complex insecure passwords become a thing of the past.

 

Our vision is to make the highest levels of cybersecurity available to organizations and consumers alike, solving complexity and scalability issues by managing high volumes of digital credentials.

 

We have been delivering trusted solutions to high profile customers for over 20 years. Our team of experts has deployed millions of identities to governments, most of the largest aerospace and defence corporations, and major financial services and healthcare organizations, as well as leading telecommunications, cloud services and information technology firms, providing industry-leading employee and customer credential management systems.

 

For more information visit: www.intercede.com

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSSIFWFFUSESL
Date   Source Headline
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20247:00 amRNSTransaction in Own Shares
14th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20247:00 amRNSTransaction in Own Shares
8th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSNotice of Results & Investor Presentation
25th Oct 20247:00 amRNSShare Buyback Programme
11th Oct 20248:38 amRNSDirector/PDMR Shareholding
8th Oct 20247:00 amRNSTrading Update
1st Oct 20247:00 amRNSNotification of Trading Update and H1 FY25 Results
30th Sep 20247:00 amRNSContract Orders and Renewals
25th Sep 202412:51 pmRNSResult of AGM
20th Sep 202411:45 amRNSDirector/PDMR Shareholding
18th Sep 20247:00 amRNSContract Orders and Renewals
2nd Sep 20247:00 amRNSContract Orders and Subscription Renewals
30th Aug 20247:00 amRNSNotice of AGM and Publication of Annual Report
4th Jul 20243:58 pmRNSIssue of Equity & Total Voting Rights
28th Jun 20243:49 pmRNSIssue of Equity & Total Voting Rights
26th Jun 20247:00 amRNSPartnership with Carahsoft Technology Corp
19th Jun 20246:25 pmRNSHolding(s) in Company
18th Jun 20249:17 amRNSHolding(s) in Company
18th Jun 20247:15 amRNSDirector/PDMR Shareholding and Issue of Equity
18th Jun 20247:00 amRNSFinal Results
5th Jun 20247:00 amRNSNotice of Results & Investor Presentation
16th May 202412:00 pmRNSCapital Markets Day - Agenda Update
14th May 20246:17 pmRNSShare Incentive Scheme
26th Apr 202410:02 amRNSShare Incentive Scheme
23rd Apr 20247:00 amRNSCapital Markets Day
8th Apr 20247:00 amRNSTrading Update
2nd Apr 20247:00 amRNSContract and Subscription Renewals
25th Mar 20243:38 pmRNSHolding(s) in Company
25th Mar 20243:35 pmRNSHolding(s) in Company
22nd Mar 20247:00 amRNSNew Orders and Trading Update
21st Mar 20247:00 amRNSNew Product Announcement: Launch of MyID MFA v5
6th Feb 20247:00 amRNSDirector/PDMR Shareholding
29th Jan 20247:00 amRNSNew Orders
18th Jan 20249:55 amRNSDirector/PDMR Shareholding
3rd Jan 20247:00 amRNSMajor New Contract Win
7th Dec 20237:00 amRNSUpdate on Major New Contract Win
5th Dec 202312:30 pmRNSMajor New Contract with Large US Federal Agency
22nd Nov 20237:00 amRNSDirector/PDMR Shareholding
21st Nov 20237:01 amRNSNew Contract and Renewal Orders
21st Nov 20237:00 amRNSHalf-year Report
7th Nov 20237:00 amRNSContract and Renewals Orders
25th Oct 20234:44 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.